Orasi Medical, a neurodiagnostic company, combines magnetoencephalography (MEG) and a unique, proprietary software platform to (1) diagnose central nervous system (CNS) diseases and (2) improve the development of therapeutics to treat these devastating CNS disorders.
Orasi has developed a non-invasive platform to detect and aid in an objective diagnosis of complex neurological and psychiatric disorders. Orasi’s technology utilizes a fully automated platform to collect and analyze MEG scans and will deliver (via the web) a diagnostic report to a physician or clinical trial results to a pharmaceutical development team.
Orasi’s initial focus is the development of a diagnostic test for Alzheimer’s disease.
In addition, Orasi provides products and services for bio-pharmaceutical companies to improve and accelerate the development of CNS drugs for a number of diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, tinnitus, schizophrenia, and depression as well as many others. Our flagship product, Orasi Index™ accelerates neurological and psychiatric drug development, reduces costs and improves clinical trial outcomes by:
- Confirming the drug reaches the brain
- Identifying the most effective dose
- Selecting the best patients, and
- Measuring drug effect earlier and more accurately.
Orasi has the largest database of MEG brain scans, MEG biomarkers and supporting clinical data for an expanding range of drug signatures and disease patterns.